Cargando…

Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis

Detalles Bibliográficos
Autores principales:	Bierman, WFW, Humphreys, EH, van Agtmael, MA, Boucher, CA, Rutherford, GW
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The International AIDS Society 2010
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3112830/ http://dx.doi.org/10.1186/1758-2652-13-S4-O18

Ejemplares similares

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
por: Pillay, D, et al.
Publicado: (2010)

The MONET trial: correlation between Hepatitis C coinfection and HIV RNA responses during darunavir/ritonavir monotherapy, for patients with HIV RNA <50 copies/mL at baseline
por: Arribas, Jose R, et al.
Publicado: (2010)

Mitochondrial ageing and antiretroviral therapy exposure
por: Payne, BAI, et al.
Publicado: (2010)

Detrimental clinical interaction between ritonavir-boosted protease inhibitors and vinblastin in HIV-infected patients with Hodgkin lymphoma
por: Cingolani, A, et al.
Publicado: (2010)

Comparative efficacy and safety of regimens including ritonavir-boosted lopinavir or nevirapine in antiretroviral-naïve HIV-1-infected individuals
por: Pereira, A, et al.
Publicado: (2010)

Is ultrasound axillary staging less accurate in invasive lobular breast cancer than in ductal breast cancer?
por: Sankaye, P, et al.
Publicado: (2012)

Ritonavir inhibits NF-AT activation through modulation of the PI-3 kinase/Akt Ppathway
por: Pati, Shibani, et al.
Publicado: (2006)

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children
por: Zhang, C, et al.
Publicado: (2010)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

Premise: traditional disease-modifying antirheumatic drugs are less effective and safe than targeted therapy with biologic response modifiers in rheumatoid arthritis
por: Fleischmann, R
Publicado: (2003)

Whole-heart contrast-enhanced coronary magnetic resonance angiography in less than 5 minutes using gradient echo interleaved EPI
por: Bhat, Himanshu, et al.
Publicado: (2009)

OP4-3 Molecular detection of respiratory viruses: routine application on 522 samples taken in children less than 2 year old
por: Escuret, V., et al.
Publicado: (2009)

Balanced Crystalloid Use Is Associated With Haemodynamic Stability And Less Need For Vasopressors in Patients Receiving Renal Transplantation Compared To 0.9% Saline
por: Pfortmueller, CA, et al.
Publicado: (2015)

Is Ritonavir-Boosted Atazanavir a Risk for Cholelithiasis Compared to Other Protease Inhibitors?
por: Hamada, Yohei, et al.
Publicado: (2013)

Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors
por: Manasa, Justen, et al.
Publicado: (2017)

Liver safety of two nucleoside analogs plus efavirenz, nevirapine or a ritonavir-boosted protease inhibitor in HIV/HCV-coinfected drug-naïve patients
por: Macías, J, et al.
Publicado: (2010)

Less invasive surgery of the proximal aorta
por: Risteski, P, et al.
Publicado: (2013)

Screening for new antiretroviral targets
por: Fassati, Ariberto
Publicado: (2013)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

HIV-1 envelope trimer elicits higher neutralizing antibody responses than monomeric gp120
por: Kovacs, JM, et al.
Publicado: (2012)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
por: Dickinson, L, et al.
Publicado: (2010)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Antiretroviral drug resistance and viral tropism in HIV-1 CRF06_cpx infected patients failing antiretroviral (ARV) therapy
por: Pauskar, Merit, et al.
Publicado: (2014)

7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis
por: Giannini, EH, et al.
Publicado: (2008)

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR
por: Wyatt, Christina M., et al.
Publicado: (2020)

International perspectives on adherence and resistance to HIV antiretroviral therapy
por: Bangsberg, D
Publicado: (2010)

Patients’ expectations versus doctors’ expectations in antiretroviral therapy
por: Largu, Alexandra Maria, et al.
Publicado: (2014)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Phenotypic characterization of virological failure following lopinavir/ritonavir monotherapy using full-length gag–protease genes
por: Sutherland, Katherine A., et al.
Publicado: (2014)

Ritonavir-Boosted Darunavir Plus Two Nucleoside Reverse Transcriptase Inhibitors versus Other Regimens for Initial Antiretroviral Therapy for People with HIV Infection: A Systematic Review
por: Balayan, Tatevik, et al.
Publicado: (2017)

HIV replication and evolution in patients on highly active antiretroviral therapy
por: Siliciano, Robert F
Publicado: (2006)

Antiretroviral treatment and association with prematurity in perinatal HIV-exposed children
por: Tudor, Ana Maria, et al.
Publicado: (2014)

Low-level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial
por: Clumeck, N, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_4gpf69b7mdr69ejie8u2pp8psd